Mersalyl

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mersalyl
Accession Number
DB09338
Type
Small Molecule
Groups
Approved
Description
Not Available
Structure
Thumb
Synonyms
  • Mersal
Product Ingredients
IngredientUNIICASInChI Key
Mersalyl sodium5X1IO031V8492-18-2WWKZBHGJCDECFG-UHFFFAOYSA-L
Categories
UNII
7RDI07K19U
CAS number
486-67-9
Weight
Average: 483.87
Monoisotopic: 485.07623
Chemical Formula
C13H17HgNO6
InChI Key
HQRSUIDICNOLPX-UHFFFAOYSA-M
InChI
InChI=1S/C13H16NO5.Hg.H2O/c1-9(18-2)7-14-13(17)10-5-3-4-6-11(10)19-8-12(15)16;;/h3-6,9H,1,7-8H2,2H3,(H,14,17)(H,15,16);;1H2/q;+1;/p-1
IUPAC Name
2-(2-{[3-(hydroxymercurio)-2-methoxypropyl]carbamoyl}phenoxy)acetic acid
SMILES
COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mersalyl.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Mersalyl.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Mersalyl.Illicit
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Mersalyl.Experimental, Illicit, Withdrawn
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mersalyl.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mersalyl.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Mersalyl.Illicit, Investigational, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Mersalyl.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Mersalyl.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mersalyl.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Mersalyl.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mersalyl.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Mersalyl.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mersalyl.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mersalyl.Approved, Illicit
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Mersalyl.Experimental
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Mersalyl.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Mersalyl.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mersalyl.Approved, Illicit, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Mersalyl.Approved, Illicit, Investigational
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mersalyl.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mersalyl.Approved, Illicit
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Mersalyl.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mersalyl.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mersalyl.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Mersalyl.Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Mersalyl.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Mersalyl.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Mersalyl.Approved, Illicit
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Mersalyl.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mersalyl.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Mersalyl.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Mersalyl.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Mersalyl.Approved, Illicit
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mersalyl.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mersalyl.Approved, Investigational, Vet Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mersalyl.Approved, Vet Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mersalyl.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Mersalyl.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Mersalyl.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Mersalyl.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mersalyl.Approved
Sodium phosphateMersalyl may increase the nephrotoxic activities of Sodium phosphate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mersalyl.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Mersalyl.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Mersalyl.Experimental
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mersalyl.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C11336
PubChem Compound
443130
PubChem Substance
310265214
ChemSpider
11337655
ChEBI
6771
ChEMBL
CHEMBL1201330
Wikipedia
Mersalyl
ATC Codes
C03BC01 — Mersalyl

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility9.9 mg/mLALOGPS
logP-0.07ALOGPS
logP-0.74ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)3.24ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area105.09 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity69.75 m3·mol-1ChemAxon
Polarizability30.58 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenoxyacetic acid derivatives
Direct Parent
Phenoxyacetic acid derivatives
Alternative Parents
Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Carboxylic acid salts / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Organic transition metal salts / Carboxylic acids / Monocarboxylic acids and derivatives / Dialkyl ethers
show 6 more
Substituents
Phenoxyacetate / Phenoxy compound / Phenol ether / Alkyl aryl ether / Carboxylic acid salt / Carboximidic acid / Carboximidic acid derivative / Carboxylic acid derivative / Carboxylic acid / Dialkyl ether
show 16 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monocarboxylic acid (CHEBI:6771)

Drug created on November 26, 2015 17:19 / Updated on December 01, 2017 17:22